STRS Ohio’s Elicio Therapeutics ELTX Stock Holding History

STRS Ohio’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,960	Closed	-$41K	–	2111
2022 Q1	$41K	Hold	1,960	–	–	﹤0.01%	1968
2021 Q4	$56K	Sell	1,960 -1,590	-45%	-$80.4K	﹤0.01%	1987
2021 Q3	$346K	Hold	3,550	–	–	﹤0.01%	1623
2021 Q2	$462K	Buy	3,550 +3,410	+2,436%	+$492K	﹤0.01%	1588
2021 Q1	$25K	Buy	+140	New	+$27K	﹤0.01%	2098

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

STRS Ohio's ELTX Position: Q2 2022 in Review

STRS Ohio sold out of Elicio Therapeutics (ELTX) in Q2 2022, closing a stake of 1,960 shares — an estimated $41K sold.

STRS Ohio first reported a position in ELTX in Q1 2021 and held it in 5 quarters. The position peaked at $462K in Q2 2021. 43 funds tracked by Wall St. Rank hold ELTX as of Q2 2022.

STRS Ohio reported no remaining Elicio Therapeutics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 1,960 Elicio Therapeutics shares in Q2 2022, an estimated $41K.
STRS Ohio first reported a position in Elicio Therapeutics in Q1 2021 and held it in 5 quarters.
STRS Ohio's Elicio Therapeutics position peaked at $462K in Q2 2021.
43 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.